Rosetta Genomics Ltd. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by SABBY MANAGEMENT, LLC, was filed 27 Apr 2018.
Rosetta Genomics Ltd.: what insiders have been doing
Rosetta Genomics Ltd. is a listed company. Filings by its managers are published through SEC (Form 4). The past year has been quiet: not a single insider filing for Rosetta Genomics Ltd. The previous disclosure was published on 27 April 2018.
Since 2018, the database holds 28 purchases and no sales by insiders of the company.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Since the insiders bought
- -98.0%Entry US$0.43 · Close at T+365 US$0.01
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
- 7,085 shares@ US$0.351.6% of flowADR Shares (each one equal to 2 ordinary shares)SEC:0001535610-18-000082:0Canonical exit: 25 Jul 2018 (T+90)
- 20,229 shares@ US$0.42615.6% of flowADR Shares (each one equal to 2 ordinary shares)SEC:0001535610-18-000070:1Canonical exit: 14 Jun 2018 (T+90)
- 1,400 shares@ US$0.42110.4% of flowADR Shares (each one equal to 2 ordinary shares)SEC:0001535610-18-000070:0Canonical exit: 14 Jun 2018 (T+90)
- 9,247 shares@ US$0.42942.6% of flowADR Shares (each one equal to 2 ordinary shares)SEC:0001535610-18-000070:2Canonical exit: 14 Jun 2018 (T+90)
- 33,413 shares@ US$0.43539.5% of flowADR Shares (each one equal to 2 ordinary shares)SEC:0001535610-18-000070:3Canonical exit: 14 Jun 2018 (T+90)
- 9 shares@ US$0.42010.0% of flowADR Shares (each one equal to 2 ordinary shares)SEC:0001535610-18-000070:4Canonical exit: 14 Jun 2018 (T+90)
- 800 shares@ US$0.41990.2% of flowADR Shares (each one equal to 2 ordinary shares)SEC:0001535610-18-000069:0Canonical exit: 12 Jun 2018 (T+90)
- 4,271 shares@ US$0.421.2% of flowADR Shares (each one equal to 2 ordinary shares)SEC:0001535610-18-000069:1Canonical exit: 12 Jun 2018 (T+90)
- 200 shares@ US$0.420.1% of flowADR Shares (each one equal to 2 ordinary shares)SEC:0001535610-18-000069:2Canonical exit: 12 Jun 2018 (T+90)
- 17,900 shares@ US$0.4244.9% of flowADR Shares (each one equal to 2 ordinary shares)SEC:0001535610-18-000069:3Canonical exit: 12 Jun 2018 (T+90)
- 50,020 shares@ US$0.420113.6% of flowADR Shares (each one equal to 2 ordinary shares)SEC:0001535610-18-000069:4Canonical exit: 12 Jun 2018 (T+90)
- 15,025 shares@ US$0.42054.1% of flowADR Shares (each one equal to 2 ordinary shares)SEC:0001535610-18-000069:5Canonical exit: 13 Jun 2018 (T+90)
- 34 shares@ US$0.420.0% of flowADR Shares (each one equal to 2 ordinary shares)SEC:0001535610-18-000069:6Canonical exit: 13 Jun 2018 (T+90)
- 3,566 shares@ US$0.421.0% of flowADR Shares (each one equal to 2 ordinary shares)SEC:0001535610-18-000069:7Canonical exit: 13 Jun 2018 (T+90)
- 13,545 shares@ US$0.423.7% of flowADR Shares (each one equal to 2 ordinary shares)SEC:0001535610-18-000069:8Canonical exit: 13 Jun 2018 (T+90)
- 14,400 shares@ US$0.42053.9% of flowADR Shares (each one equal to 2 ordinary shares)SEC:0001535610-18-000069:9Canonical exit: 13 Jun 2018 (T+90)
- 20,373 shares@ US$0.41995.6% of flowADR Shares (each one equal to 2 ordinary shares)SEC:0001535610-18-000068:0Canonical exit: 10 Jun 2018 (T+90)
- 454 shares@ US$0.4010.1% of flowADR Shares (each one equal to 2 ordinary shares)SEC:0001535610-18-000068:1Canonical exit: 10 Jun 2018 (T+90)
- 2,604 shares@ US$0.41990.7% of flowADR Shares (each one equal to 2 ordinary shares)SEC:0001535610-18-000068:2Canonical exit: 10 Jun 2018 (T+90)
- 11,521 shares@ US$0.413.1% of flowADR Shares (each one equal to 2 ordinary shares)SEC:0001535610-18-000068:3Canonical exit: 10 Jun 2018 (T+90)
- 21,800 shares@ US$0.41175.8% of flowADR Shares (each one equal to 2 ordinary shares)SEC:0001535610-18-000068:4Canonical exit: 10 Jun 2018 (T+90)
- 24,600 shares@ US$0.41856.7% of flowADR Shares (each one equal to 2 ordinary shares)SEC:0001535610-18-000068:5Canonical exit: 10 Jun 2018 (T+90)
- 24,162 shares@ US$0.41866.6% of flowADR Shares (each one equal to 2 ordinary shares)SEC:0001535610-18-000068:6Canonical exit: 10 Jun 2018 (T+90)
- 10,605 shares@ US$0.41892.9% of flowADR Shares (each one equal to 2 ordinary shares)SEC:0001535610-18-000068:7Canonical exit: 10 Jun 2018 (T+90)
- 12,390 shares@ US$0.41013.3% of flowADR Shares (each one equal to 2 ordinary shares)SEC:0001535610-18-000068:8Canonical exit: 10 Jun 2018 (T+90)
25 of 28 declarations
About Rosetta Genomics Ltd.
Rosetta Genomics Ltd. is a company focused on developing DNA-based diagnostic tests for cancer. It aims to leverage genomics to enhance the diagnosis and treatment of oncological diseases.
